Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Neurology|May 13, 2016
Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort studyMathias Buttmann, Linda Seuffert, Uwe Mäder, et al.
The Journal of Clinical Endocrinology and Metabolism|September 27, 2014
Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patientsFrederik A Verburg, Uwe Mäder, Christoph Reiners, et al.
European Journal of Endocrinology|January 23, 2009
Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastasesFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Clinical Endocrinology|December 11, 2008
Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinomaFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Clinical Endocrinology|March 25, 2018
The effects of the Union for International Cancer Control/American Joint Committee on Cancer Tumour, Node, Metastasis system version 8 on staging of differentiated thyroid cancer: a comparison to version 7Frederik A Verburg, Uwe Mäder, Markus Luster, et al.
Thyroid : Official Journal of the American Thyroid Association|April 19, 2018
Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and 131I AblationFrederik A Verburg, Uwe Mäder, Luca Giovanella, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 24, 2015
Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortalityAlexis Vrachimis, Burkhard Riemann, Uwe Mäder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 14, 2015
Determinants of successful ablation and complete remission after total thyroidectomy and ¹³¹I therapy of paediatric differentiated thyroid cancerFrederik A Verburg, Uwe Mäder, Markus Luster, et al.
Clinical Endocrinology|March 6, 2015
The TNM system (version 7) is the most accurate staging system for the prediction of loss of life expectancy in differentiated thyroid cancerKarina Tanase, Elena-Daphne Thies, Uwe Mäder, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|November 15, 2017
Only a Rapid Complete Biochemical Remission After 131I-Therapy is Associated with an Unimpaired Life Expectancy in Differentiated Thyroid CancerFrederik A Verburg, Uwe Mäder, Inge Grelle, et al.
Pageof 3